Wockhardt Limited has informed the Exchange regarding a press release dated Jun 28, 2024, titled "Globally renowned US body Clinical and Laboratory Standards Institute (CLSI) awards high susceptibility breakpoints to Zaynich (Zidebactam/Cefepime- WCK 5222)".